



External Quality Assessment Program for Chemokine CXCL13

Labquality is announcing a new EQA scheme for chemokine CXCL13, a biomarker for neuroborreliosis. Each round will include two samples that should be analysed as regular patient samples. The participants submit their results through the electronic platform LabScala and results are processed by the EQA Coordinator. Result evaluations including comments by the Scheme Expert will be published in the final report distributed to the participants.

Round 1, 2022 will be a pilot study free of charge for a limited number of participants. The pilot round will open in September/October. Two rounds will be included in the program of 2023.

5965 Chemokine CXCL13

- Samples:** 2 liquid samples
Distribution: 1, 2022 September/October – free-of-charge pilot study
Participation: Limited number of samples available
Registration: Please register by **August 15th, 2022** only via [this link](#).

Please note, if you have already registered through the general pilot registration link earlier this year, no further actions are needed.

For more information

Labquality's customer service info@labquality.fi or

Satu Eklund

EQA Coordinator

satu.eklund@labquality.com

+358 45 773 10787

Heidi Berghäll

Development Manager

heidi.berghall@labquality.com

+358 50 356 0503